Michael Falcone Insider Acquisition for 1,000 Shares of MMA Capital Management, (MMAC); Opus Point Partners Management Lowered Gilead Sciences (GILD) Stake

Gilead Sciences, Inc. (NASDAQ:GILD) Logo

Opus Point Partners Management Llc decreased Gilead Sciences Inc (GILD) stake by 69.25% reported in 2017Q4 SEC filing. Opus Point Partners Management Llc sold 6,925 shares as Gilead Sciences Inc (GILD)’s stock rose 1.93%. The Opus Point Partners Management Llc holds 3,075 shares with $220,000 value, down from 10,000 last quarter. Gilead Sciences Inc now has $84.75 billion valuation. The stock decreased 2.53% or $1.69 during the last trading session, reaching $65.19. About 13.62 million shares traded or 75.41% up from the average. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since May 4, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

The CEO and President of Mma Capital Management – Llc, Michael Falcone has made an unexpected deal in the company that is amounting to $27,930 US Dollars. As disclosed in the U.S. Security & Exchange Commission legal document filed on 03-05-2018, Michael acquired 1,000 shares at average stock price per share of $27.9. It seems he is very active lately as in the last month, he silently bought additional 2,712 shares of the company, worth $75,444 USD. Michael Falcone right now holds 186,057 shares which make up roughly 3.29% of the Maryland-based company’s total market cap.

Another recent and important MMA Capital Management, LLC (NASDAQ:MMAC) news was published by Prnewswire.com which published an article titled: “MMA Capital Management Announces Investor Conference Call” on April 19, 2018.

MMA Capital Management, LLC creates and manages investments in housing and renewable energy sectors in the United States and internationally. The company has market cap of $156.52 million. The Company’s bond portfolio primarily comprises multifamily tax-exempt bonds, as well as other real estate related bond investments. It has a 8.36 P/E ratio. The firm offers leveraged bonds; low-income housing tax credits; asset management and administrative services to a limited liability firm and a commercial bank; guarantees to third parties related to the receipt of tax credits; and debt capital to develop build, and operate renewable energy systems.

The stock decreased 0.72% or $0.2 during the last trading session, reaching $27.7. About 2,363 shares traded. MMA Capital Management, LLC (NASDAQ:MMAC) has risen 17.32% since May 4, 2017 and is uptrending. It has outperformed by 5.77% the S&P500.

Investors sentiment decreased to 0.8 in 2017 Q4. Its down 0.23, from 1.03 in 2017Q3. It worsened, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. City Trust Fl reported 4,169 shares or 0.14% of all its holdings. 15,727 are held by Kidder Stephen W. Moreover, Colrain Cap Limited Liability Corp has 2.09% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 35,230 shares. Heritage Wealth accumulated 0.81% or 26,523 shares. Hanson Mcclain Incorporated has invested 0.01% in Gilead Sciences, Inc. (NASDAQ:GILD). Stonebridge Capital Mgmt reported 53,675 shares stake. Kelly Lawrence W Associates Ca holds 29,605 shares or 0.39% of its portfolio. Rowland Communications Invest Counsel Adv has invested 0.15% in Gilead Sciences, Inc. (NASDAQ:GILD). Cap Guardian Tru reported 273,511 shares stake. Moreover, Stanley has 0.54% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Bank Of The West owns 84,581 shares for 0.76% of their portfolio. Silvercrest Asset Mngmt Group Incorporated Limited owns 47,021 shares. Comerica Securities owns 37,061 shares for 0.33% of their portfolio. First Foundation accumulated 0.26% or 67,006 shares. Daiwa Sb Ltd invested in 0.01% or 530 shares.

Since January 2, 2018, it had 0 buys, and 20 selling transactions for $40.81 million activity. Washington Robin L sold $401,566 worth of stock or 5,000 shares. On Monday, March 12 Cogan John Francis sold $472,065 worth of Gilead Sciences, Inc. (NASDAQ:GILD) or 5,833 shares. Shares for $8.02M were sold by Meyers James R on Tuesday, January 16. Shares for $1.11 million were sold by Alton Gregg H. Another trade for 50,000 shares valued at $3.68M was made by MARTIN JOHN C on Tuesday, January 2. WILSON GAYLE E had sold 60,000 shares worth $4.68 million.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: “Gilead Sciences: The Sales Tell The Story” on May 03, 2018, also Seekingalpha.com with their article: “AbbVie’s Mavyret Could Punish Gilead Tuesday” published on April 30, 2018, Schaeffersresearch.com published: “3 Drug Stocks Near the Bottom of the Nasdaq Today” on May 02, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Gilead: Will Medicare Boost Yescarta Sales?” published on April 23, 2018 as well as Seekingalpha.com‘s news article titled: “Gilead: Yescarta Faces Unforeseen Hurdles” with publication date: April 16, 2018.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 130 analyst reports since July 29, 2015 according to SRatingsIntel. Leerink Swann initiated the shares of GILD in report on Friday, February 5 with “Outperform” rating. Cowen & Co maintained the stock with “Buy” rating in Tuesday, May 30 report. As per Wednesday, August 31, the company rating was maintained by Jefferies. The stock has “Buy” rating by RBC Capital Markets on Wednesday, October 4. Credit Suisse maintained the shares of GILD in report on Wednesday, February 3 with “Outperform” rating. Maxim Group maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, October 28 with “Buy” rating. As per Tuesday, September 6, the company rating was upgraded by Jefferies. Bank of America upgraded the shares of GILD in report on Monday, January 18 to “Neutral” rating. William Blair initiated Gilead Sciences, Inc. (NASDAQ:GILD) on Thursday, August 31 with “Buy” rating. The firm has “Outperform” rating by RBC Capital Markets given on Monday, October 3.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart